MiR‐940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|7|819-824

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.7, 2015-07, pp. : 819-824

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Abnormal expression of miR‐1 in breast carcinoma as a potent prognostic factor

By  

Cancer Science, Vol. 106, Iss. 11, 2015-11 ,pp. : 1642-1650

John Wiley & Sons Inc

Access to resources Recommend Favorite

miR‐181a induces sorafenib resistance of hepatocellular carinoma cells through downregulation of RASSF1 expression

By  

Cancer Science, Vol. 107, Iss. 9, 2016-09 ,pp. : 1256-1262

John Wiley & Sons Inc

Access to resources Recommend Favorite

Histidine‐rich calcium binding protein promotes growth of hepatocellular carcinoma in vitro and in vivo

By  

Cancer Science, Vol. 106, Iss. 10, 2015-10 ,pp. : 1288-1295

John Wiley & Sons Inc

Access to resources Recommend Favorite

Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma

By  

Cancer Science, Vol. 106, Iss. 8, 2015-08 ,pp. : 1016-1022

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 611-617

John Wiley & Sons Inc

Access to resources Recommend Favorite